On July 3, 2019, Jacobio reported that JAB-3312, an oral small-molecule anti-tumor drug has obtained FDA’s approval for clinical study (Press release, Jacobio Pharmaceuticals, JUL 3, 2019, View Source [SID1234538526]). JAB-3312 was independently designed and developed by Jacobio which owns its intellectual property right worldwide. This is the second small-molecule anti-tumor drug approved for clinical research after JAB-3068 ,which has been in phase IIa clinical study.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

JAB-3312 can block the KRAS-MAPK signaling pathway and can be used for the treatment of multiple solid tumors, including non-small-cell lung cancer, colorectal cancer and pancreatic cancer. Meanwhile, it can also attenuate the tumor immunosuppressive microenvironment and enhance the efficacy of existing tumor immunotherapies.